Prof Fred Saad discusses the impact of bone-protecting agents in PEACE-3.

His study shows that combining radium with enzalutamide improves survival rates in mCRPC patients. The use of bone protective agents has shifted from optional to mandatory due to safety concerns when using this treatment regimen.

Patients using these agents experience better radiographic progression-free survival and overall survival, highlighting their role in enhancing treatment efficacy and suggesting their importance in current treatment protocols.